The specter of generic rivalry has repeatedly loomed around copyright’s famous drug, Sildenafil, sparking questions about the future of related pharmaceutical stakes. While initial times saw impressive profits, the exclusivity lapse has allowed the path for discounted substitutes, likely diminishing earnings and posing a real hazard for stakehold